Prevalence of nontuberculous mycobacterial pulmonary disease, Germany, 2009-2014

Emerging Infectious Diseases

Volumn 22, Issue 6, 2016, Pages 1102-1105

  Ringshausen, Felix C ^a,b   Wagner, Dirk ^c   de Roux, Andrés ^d   Diel, Roland ^a,e   Hohmann, David ^f   Hickstein, Lennart ^g   Welte, Tobias ^a,b   Rademacher, Jessica ^b  

^a German Center for Lung Research   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d Pneumologische Praxis am Schloss Charlottenburg   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f Health Risk Institute ^*  (Germany)

^g Health Risk Institute   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; DIABETES MELLITUS; EMPHYSEMA; FEMALE; GERMANY; HEALTH INSURANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; ICD-10; INFLUENZA; LUNG CANCER; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MIDDLE AGED; MYCOBACTERIOPHAGE; OSTEOPOROSIS; PNEUMONIA; POPULATION; PREVALENCE; RESPIRATORY FAILURE; RHEUMATOID ARTHRITIS; ATYPICAL MYCOBACTERIOSIS; ATYPICAL MYCOBACTERIUM; BACTERIAL PNEUMONIA; COMORBIDITY; HEALTH SURVEY; HISTORY; MICROBIOLOGY; SEX FACTOR; YOUNG ADULT;

ADULT; COMORBIDITY; FEMALE; GERMANY; HISTORY, 21ST CENTURY; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; NONTUBERCULOUS MYCOBACTERIA; PNEUMONIA, BACTERIAL; POPULATION SURVEILLANCE; PREVALENCE; SEX FACTORS; YOUNG ADULT;

EID: 84969194667     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2206.151642     Document Type: Article

References (15)

1. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367-416. http://dx.doi.org/10.1164/rccm.200604-571ST
2. Thomson RM. Changing epidemiology of pulmonary nontuberculous mycobacteria infections. Emerg Infect Dis. 2010;16:1576-83. http://dx.doi.org/10.3201/eid1610.091201
3. Hoefsloot W, van Ingen J, Andrejak C, Angeby K, Bauriaud R, Bemer P, et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J. 2013;42:1604-1613. http://dx.doi.org/10.1183/09031936.00149212
4. Prevots DR, Shaw PA, Strickland D, Jackson LA, Raebel MA, Blosky MA, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med. 2010;182:970-976. http://dx.doi.org/10.1164/rccm.201002-0310OC
5. Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med. 2012;185: 881-886. http://dx.doi.org/10.1164/rccm.201111-2016OC
6. Ringshausen FC, Apel RM, Bange FC, de Roux A, Pletz MW, Rademacher J, et al. Burden and trends of hospitalisations associated with pulmonary non-tuberculous mycobacterial infections in Germany, 2005-2011. BMC Infect Dis. 2013;13:231. http://dx.doi.org/10.1186/1471-2334-13-231
7. German Federal Statistical Office. Facts and figures-state and society-Federal Statistical Office (Destatis). 2015 Sep 19 [cited 2015 Sep 19]. http://www.destatis.de/EN/FactsFigures/SocietyState/SocietyState.html
8. Andersohn F, Walker J. Characteristics and external validity of the German Health Risk Institute (HRI) Database. Pharmacoepidemiol Drug Saf. 2016;25:106-109. http://dx.doi.org/10.1002/pds.3895
9. Dean AG, Sullivan KM, Soe MM, Mir RA. OpenEpi: Open source epidemiologic statistics for public health, version 3.03a. 2015 May 4 [cited 2015 Sept 19]. http://www.OpenEpi.com
10. Wagner D, van Ingen J, Adjemian J, Lange C, Prevots DR, Griffith D, et al. Annual Prevalence and Treatment Estimates for Nontuberculous Mycobacterial Pulmonary Disease in Europe: A NTM-NET Collaborative Study. Eur Respir J. 2014;44(Suppl 58):1067. http://erj.ersjournals.com/content/44/Suppl_58/P1067
11. European Commission. Policy—European Commission. 2016 [cited 2016 Feb 21]. http://ec.europa.eu/health/rare_diseases/policy/index_en.htm
12. World Health Organization. Global Health Observatory Data Repository. 2015 [cited 2016 Feb 21]. http://apps.who.int/ghodata/
13. Andréjak C, Nielsen R, Thomsen VO, Duhaut P, Sorensen HT, Thomsen RW. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax. 2013;68: 256-262. http://dx.doi.org/10.1136/thoraxjnl-2012-201772
14. van Ingen J, Adjemian J, Morimoto K, Wagner D, Lange C, Haworth C, et al. Comparison of treatment practices for nontuberculous mycobacterial pulmonary disease in Japan, Europe, and the United States. Eur Respir J. 2014;44 (Suppl 58):1066.
15. Aksamit TR, Carretta E, Daley CL, O’Donnell AE, Thomashow B, Dominik R, et al. The Bronchiectasis Research Registry: a collaborative research cohort for non-cystic fibrosis bronchiectasis [abstract]. Am J Respir Crit Care Med. 2012;185:A3654.